2-溴-3-硝基-6-氯吡啶 | 91678-23-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 2-溴-3-硝基-6-氯吡啶
• 中文别名: 2-溴-6-氯-3-硝基吡啶
• 英文名称: 2-bromo-6-chloro-3-nitropyridine
• CAS: 91678-23-8
• 化学式: C₅H₂BrClN₂O₂
• 分子量: 237.44
• InChiKey: WISCKHBEOBONJA-UHFFFAOYSA-N

物化性质

• 沸点：
  277.2±35.0℃ (760 Torr)
• 密度：
  1.936±0.06 g/cm3 (20 ºC 760 Torr)
• 闪点：
  121.5±25.9℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-6-chloro-3-nitropyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-6-chloro-3-nitropyridine
CAS number: 91678-23-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H2BrClN2O2
Molecular weight: 237.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-3-硝基-6-氯吡啶 在 4-二甲氨基吡啶 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 氯(2-二环己基膦基-2',6'-二异丙氧基-1,1'-联苯)[2-(2-氨基乙基苯基)]钯(II) 、 sodium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 methyl 5-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1-[(4-methylbenzene)sulfonyl]-1H-pyrrolo[2,3-c]pyridine-7-carboxylate
  参考文献：
  名称：

  ALKYNYL ALCOHOLS AND METHODS OF USE

  摘要：

  该发明涉及具有以下结构的化合物（0）：其中A1-A8，R4和R5分别具有如本文所述的含义。 公式（0）的化合物及其药物组成物在治疗观察到NF-kB信号不受欢迎或过度激活的疾病和紊乱中是有用的。

  公开号：

  US20150057260A1
• 作为产物：
  描述：

  2-氨基-3-硝基-6-氯吡啶 在 亚硝酸特丁酯 、 copper(ll) bromide 作用下， 以 乙腈 为溶剂， 反应 0.5h， 以81%的产率得到2-溴-3-硝基-6-氯吡啶
  参考文献：
  名称：

  [EN] ALKYNYL ALCOHOLS AND METHODS OF USE
  [FR] ALCOOLS ALCYNYLIQUES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  该发明涉及以下式的化合物（0）：其中A1-A8，R4和R5分别具有如本文所述的含义。该式（0）的化合物及其药物组合物在治疗观察到NF-kB信号不良或过度激活的疾病和紊乱中是有用的。

  公开号：

  WO2015025026A1

文献信息

• Heterobicyclic amide compounds
  申请人：Kuehne Holger

  公开号：US20070185154A1

  公开（公告）日：2007-08-09

  Compounds of formula I processes for their preparation and pharmaceutical compositions comprising them.

  公式I的化合物及其制备方法和包含它们的药物组合物。
• [EN] ALKYNYL ALCOHOLS AND METHODS OF USE<br/>[FR] ALCOOLS ALCYNYLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015025026A1

  公开（公告）日：2015-02-26

  The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

  该发明涉及以下式的化合物（0）：其中A1-A8，R4和R5分别具有如本文所述的含义。该式（0）的化合物及其药物组合物在治疗观察到NF-kB信号不良或过度激活的疾病和紊乱中是有用的。
• [EN] HETEROARYL DERIVATIVES OF FORMULA (I) AS ATF4 INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROARYLES DE FORMULE (I) UTILISÉS EN TANT QU'INHIBITEURS D'ATF4
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019193540A1

  公开（公告）日：2019-10-10

  The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein A, C, D, L2, L3, R1, R2, R3, R4, R 5, R6, z2, z4, z5, and z6 are as defined herein; or salts thereof. The compounds of the invention are inhibitors of the ATF4 pathway and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及取代杂环芳基衍生物。具体来说，该发明涉及符合以下式（I）的化合物，其中 A、C、D、L2、L3、R1、R2、R3、R4、R5、R6、z2、z4、z5 和 z6 如本文中所定义；或其盐。该发明的化合物是ATF4途径的抑制剂，可用于治疗癌症、癌前综合征以及与激活的未折叠蛋白反应途径相关的疾病，如阿尔茨海默病、脊髓损伤、创伤性脑损伤、缺血性中风、中风、糖尿病、帕金森病、亨廷顿病、克雅氏病、相关朊病、进行性核上性麻痹、肌萎缩侧索硬化、心肌梗死、心血管疾病、炎症、纤维化、肝脏慢性和急性疾病、肺部慢性和急性疾病、肾脏慢性和急性疾病、慢性创伤性脑病（CTE）、神经退行性疾病、痴呆、认知障碍、动脉粥样硬化、眼部疾病、心律失常、器官移植以及器官运输用于移植。因此，该发明还涉及包含该发明化合物的药物组合物。该发明还涉及使用该发明化合物或包含该发明化合物的药物组合物抑制ATF4途径和治疗相关疾病的方法。
• 有机电致发光材料及其器件
  申请人：北京夏禾科技有限公司

  公开号：CN111675707B

  公开（公告）日：2023-06-06

  公开了一种有机电致发光材料及其器件。所述有机电致发光材料是一种新型三芳胺‑氮杂咔唑喹唑啉类化合物。这些化合物可用作电致发光器件中的主体材料，并能提供更好的器件性能。
• Discovery of a Potent and Highly Isoform-Selective Inhibitor of the Neglected Ribosomal Protein S6 Kinase Beta 2 (S6K2)
  作者：Stefan Gerstenecker、Lisa Haarer、Martin Schröder、Mark Kudolo、Martin P. Schwalm、Valentin Wydra、Ricardo A. M. Serafim、Apirat Chaikuad、Stefan Knapp、Stefan Laufer、Matthias Gehringer

  DOI：10.3390/cancers13205133

  日期：——

  covalent inhibitor engaging a cysteine located in the hinge region in the fibroblast growth factor receptor kinase (FGFR) 4 via a nucleophilic aromatic substitution (SNAr) reaction. The title compound shows a high selectivity over kinases with an equivalently positioned cysteine, as well as in a larger kinase panel. A good stability towards glutathione and Nα-acetyl lysine indicates a non-promiscuous

  核糖体蛋白 S6 激酶 β 2 (S6K2) 被认为在恶性细胞增殖中起重要作用，但与其密切相关的同源物 S6 激酶 β 1 (S6K1) 相比研究不足。为了更好地了解 S6K2 的生物学功能，需要化学探针，但 S6K2 和 S6K1 之间的高度相似性使得用小分子选择性地处理 S6K2 变得具有挑战性。我们能够从已知的 S6K1 选择性抑制剂中设计出第一个有效且高度同种型特异性的 S6K2 抑制剂，该抑制剂通过与位于成纤维细胞生长因子受体激酶 (FGFR) 4 中的铰链区的半胱氨酸结合的共价抑制剂通过亲核芳族取代（SNAr）反应。标题化合物对具有同等位置半胱氨酸的激酶具有高选择性，以及在更大的激酶面板中。对谷胱甘肽和 Nα-乙酰赖氨酸的良好稳定性表明非混杂反应模式。因此，标题化合物代表了朝着研究 S6K2 特异性信号传导的高质量化学探针迈出的重要一步。